Update, November 5, 2026
Since the November 3 report, McKesson has risen to $1,098.04, up 2.67% on the day and 11.94% over the past five days, while the S&P 500 fell 3.44% and the XLV health‑care ETF rose 1.68%, underscoring the stock’s strong relative momentum.
The picture holds – the daily trend continues to ride the weekly uptrend, the price remains above the 1050 round support and well above the 957 swing‑zone stop. The breakout target of a close above $1,100 on volume above the 20‑day average has not yet been reached, and the stop at $1,042.74 (derived from $1,050 minus a quarter of the ATR) remains intact. The first crack level of $1,050 and the trend‑end level of $957 are still untested, keeping the bullish framework in place.
Recent earnings showed Q2 fiscal 2027 revenue of $111 billion and an 18% earnings lift, with management raising full‑year EPS guidance to $45.60‑$46.40, reinforcing the upside narrative (Seeking Alpha). What would change the picture? A weekly close below the 50‑day SMA at $934.81 would prompt a reassessment.
McKesson Corporation (MCK) traded near $1,005 on November 3, 2026, one day before earnings, and the balance of evidence leans positive with high conviction. The stock sits 2.5% below its October 20 peak close of $1,030.12, yet it has led both the S&P 500 and the healthcare sector over 50 days. The weekly uptrend is intact. The breakout math from here does not reach 3 to 1.
Why it matters
The newest headline is a law-firm notice, not a business event. Monteverde & Associates is investigating the fairness of the sale of Option Care Health at $32.05 a share to Clayton, Dubilier & Rice and McKesson. That puts MCK on the buying side of a deal that shareholder lawyers are now picking over. Nothing in the notice changes MCK's earnings power, and the shares did not react to it in any visible way. They rose 0.65% on the day, on volume 34.9% below the 20-day average.
The past five days are mostly a sector story. MCK gained 3.7% while the S&P 500 (via SPY) fell 2.1%. The healthcare sector fund XLV rose 2.8%, so MCK beat its sector by only 0.9 point. Most of the move came from healthcare outperforming a weak market, and only a small part from MCK itself. No news item explains the week. The stock is up 11.1% over one month and 22.3% for the year, against 10.5% for the S&P 500. Much of the good news was in the price before this week began.
The argument about MCK is lopsided in what is published, but it has two sides. The bullish case, laid out on Seeking Alpha, is that AI-driven prescription automation and faster FDA rare-disease approvals will overtake regulatory drag in 2027. It leans on 41% year-over-year profit growth in specialty and oncology. The other side sits inside that same argument: the drag is real, and the payoff is placed a year out. Insider selling is a minor point, since the chief information officer sold $797,128 of stock at $995.80 on October 15, but under a plan adopted in March.
On valuation, 14 analysts rate the stock a buy, with a mean price target of $1,026, about 2.1% above the current price. Targets range from $845 to $1,207. The average leaves little room above today's price, and the spread shows how far opinion can stretch in either direction after earnings.
What the evidence says
The long-term thesis is intact. The price is above its 40-week and 10-week averages, the 50-day average at $927.60 sits above the 200-day at $864.22, and the stock is 38.6% above its 52-week low of $725.17. The stock is in an advanced uptrend that has paused just under its high, not in a topping pattern.
For the next 2 to 6 weeks, the balance of evidence leans positive, with high conviction at 3 of 4 points. The daily trend runs with the weekly uptrend. MCK leads the S&P 500 over 50 days by 10.2 points and leads XLV by 1.5 points. The RSI of 58 shows a stock that is neither stretched nor weak. The fourth point is not earned, and the breakout has not happened yet.
The strongest case against this reading is that the stock has not confirmed anything. It has not closed above $1,030.12, volume is running well under average, and the first target is only 0.6 times the risk. Options pricing implies a 6.2% move on earnings, which dwarfs the gap to the stop at $994.23. That is why conviction is not higher. It does not tip the balance, because the trend, the relative strength and the distance above the 50-day average are all intact, and a pause under the high on light volume is not damage.
Levels that matter
The structure holds above $1,000, a round number the stock is sitting barely above. A close below it would be the first crack. Support below that comes at $967.94, a swing zone, then $950. The trend ends below the 50-day average at $927.60. Below that, the next swing zone is $909.09.
The breakout level is a daily close above $1,030.12, the 52-week high, on volume above the 20-day average. From there the targets are $1,050 and $1,100. Against a stop of $994.23 (the $1,000 round level minus a quarter of the average daily range), that is 0.6 to 1 for the first and 1.9 to 1 for the second. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target well above $1,100, or a stop much closer to the entry, to change that.
What would change the picture
A weekly close below $927.60, the 50-day average, would change the picture, because it would end the trend the evidence now describes. The non-price fact that would most likely do it is earnings guidance showing that specialty and oncology profit growth, the 41% figure the bullish case rests on, is fading.
What to watch
- Earnings, November 4, 2026: the number that matters is specialty and oncology profit growth against the 41% cited by bulls. Options imply a 6.2% move, and in five of the last eight reports the actual move was larger.
- Sector: Pfizer reports this week, and The Wall Street Journal flags an election-and-earnings week. Healthcare moves can reach MCK before its own news does.
- Valuation: the price is about 2.1% below the $1,026 mean target, inside a $845 to $1,207 range.